Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
NCT04588545Phase 2Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Dec 2020
- Primary completion
- Apr 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pertuzumab, trastuzumab in breast cancer, leptomeningeal metastasis (LM), sponsored by Moffitt Cancer Center. Started Dec 2020; status: active, not recruiting.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
breast cancerleptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT04588545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04588545.